Intrauterine Growth Restriction (IUGR) — Comprehensive Thesis Overview

1. Definition and Terminology

2. Classification

By Timing of Onset

• Early-onset FGR (< 32 weeks): Usually placental in origin; associated with severe Doppler abnormalities and preeclampsia; carries higher morbidity/mortality.
• Late-onset FGR (≥ 32 weeks): More common; milder Doppler changes; higher risk of missed diagnosis; still associated with adverse neurodevelopmental outcomes.

By Pattern (Ultrasound)

3. Etiology

Fetal Causes (~10%)

• Chromosomal anomalies: Trisomy 13, 18, 21; Turner syndrome
• Structural anomalies: Cardiac defects, gastroschisis
• Single-gene disorders
• Congenital infections: TORCH (Toxoplasma, Rubella, CMV, Herpes, Syphilis, Zika)
• Multiple gestation (twin-to-twin transfusion syndrome)

Placental Causes (~40%)

• Uteroplacental insufficiency (most common cause of asymmetric IUGR)
• Placental mosaicism
• Placenta previa, abruption
• Single umbilical artery
• Abnormal cord insertion (velamentous, marginal)

Maternal Causes (~50%)

• Vascular disease: Chronic hypertension, preeclampsia, diabetes with end-organ damage
• Thrombophilias: Antiphospholipid syndrome, Factor V Leiden
• Medical conditions: CKD, SLE, cyanotic heart disease, severe anemia
• Nutritional/lifestyle: Malnutrition, smoking, alcohol, drug use (cocaine), high altitude
• PCOS: Associated with ~1.77x increased odds of IUGR (Assessment and Management of PCOS, p. 136)
• Uterine anomalies: Fibroids, bicornuate uterus

4. Pathophysiology

1. Impaired trophoblast invasion → failure of physiological transformation of spiral arteries → high-resistance, low-flow uteroplacental circulation
2. Oxidative stress and endothelial dysfunction → villous ischemia → reduced nutrient/oxygen transfer
3. Fetal adaptive responses:
   • Redistribution of cardiac output to brain, heart, adrenals ("brain-sparing")
   • Reduced insulin-like growth factor (IGF-1) levels
   • Elevated fetal cortisol → accelerated lung maturation but impaired somatic growth
   • Progressive deterioration: reduced amniotic fluid → abnormal venous Dopplers → fetal acidemia

5. Diagnosis

Ultrasound (Primary Modality)

Doppler Studies (ISUOG Classification)

• Middle cerebral artery (MCA): Reduced PI = brain-sparing (cerebrovasodilation)
• Cerebroplacental ratio (CPR): MCA PI/UA PI <1.0 = adverse perinatal outcome predictor (especially late-onset FGR)
• Ductus venosus (DV): Absent/reversed a-wave = imminent fetal compromise

Biophysical Profile (BPP)

• Score ≤4/10 → delivery indicated
• Score 6/10 → repeat within 24 hours

Investigations for Etiology

• Detailed fetal anatomy scan
• Fetal karyotype/microarray (if early-onset, structural anomalies, or severe growth restriction)
• TORCH serology
• Maternal thrombophilia screen
• Uterine artery Doppler at 20–24 weeks (screening)

6. Management

Antenatal Surveillance Schedule

Interventions

• Aspirin (low-dose, 150 mg): Started <16 weeks in high-risk women; reduces preeclampsia and FGR by ~62% (ASPRE trial)
• Antenatal corticosteroids: Betamethasone 12 mg IM × 2 doses if delivery anticipated <34 weeks
• Magnesium sulfate: Neuroprotection if delivery <32 weeks
• Timing of delivery (ISUOG/RCOG guidelines):

• No definitive treatment exists to reverse IUGR; management is supportive and aims at optimizing timing of delivery.

Mode of Delivery

• Vaginal delivery if fetal status reassuring; continuous CTG mandatory
• C-section: REDF/absent DV, abnormal CTG, unfavorable cervix with compromise

7. Complications

Perinatal

• Stillbirth (50% of unexplained stillbirths are growth-restricted)
• Hypoxic-ischemic encephalopathy (HIE)
• Preterm birth and its sequelae
• Neonatal: hypoglycemia, polycythemia, hypothermia, necrotizing enterocolitis (NEC), RDS

Long-term (Barker Hypothesis / DOHaD)

• Neurodevelopmental: Cerebral palsy, lower IQ, ADHD, learning difficulties (especially early-onset)
• Cardiovascular: Hypertension, coronary artery disease, stroke in adulthood
• Metabolic: Type 2 diabetes, insulin resistance, dyslipidemia
• Renal: Reduced nephron number → CKD risk

8. Screening and Prevention

9. Special Considerations for a Thesis

Potential Thesis Focus Areas

1. Early vs. late-onset FGR: distinct pathophysiological entities requiring different diagnostic thresholds and management
2. Cerebroplacental ratio (CPR): emerging biomarker for late-onset FGR adverse outcomes
3. Placental growth factor (PlGF): role in angiogenic marker-based prediction and diagnosis
4. Neurodevelopmental outcomes of FGR neonates at school age
5. DOHaD and epigenetic mechanisms in IUGR
6. Optimal timing of delivery (TRUFFLE trial, GRIT trial, TIME trial outcomes)
7. IUGR in twin pregnancies: selective FGR classification (Gratacos types I–III)
8. Machine learning models for FGR prediction from first-trimester data

Key Landmark Studies

10. Summary Flowchart

Suspected FGR (EFW/AC <10th percentile)
        ↓
Confirm with serial growth scan (2–4 wks apart)
        ↓
Doppler assessment: UA, MCA, DV
        ↓
Normal Dopplers → CPR assessment → Serial surveillance
        ↓
Abnormal UA → Hospitalize → Steroids if <34 wks
        ↓
AEDF/REDF → Delivery 30–34 wks (based on DV/CTG)
        ↓
Abnormal DV a-wave / BPP ≤4 → Urgent delivery